Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Updated Data Reinforce EV-302 Regimen as SOC in Advanced Urothelial Cancer
February 15th 2025, 4:21pm
Genitourinary Cancers Symposium (ASCO GU)
Enfortumab vedotin plus pembrolizumab maintains compelling benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.
Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent
February 14th 2025, 11:06pm
Transplantation and Cellular Therapy Meetings
One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.
Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status
February 14th 2025, 10:54pm
Genitourinary Cancers Symposium (ASCO GU)
Avelumab first-line maintenance improved survival outcomes in advanced urothelial carcinoma, regardless of diabetes status.
Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL
February 14th 2025, 10:38pm
Transplantation and Cellular Therapy Meetings
MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.
Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment
February 14th 2025, 10:34pm
Transplantation and Cellular Therapy Meetings
Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.
UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC
February 14th 2025, 10:29pm
Genitourinary Cancers Symposium (ASCO GU)
UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.
Dr Albigès on Survival Outcomes With Cabozantinib Plus Nivolumab and Ipilimumab in RCC
February 14th 2025, 10:21pm
Genitourinary Cancers Symposium (ASCO GU)
Laurence Albigès, MD, PhD discusses final OS data and biomarker analyses with cabozantinib plus nivolumab and ipilimumab in intermediate- or poor-risk RCC.
Orca-T With RIC Is Safe in Advanced Hematologic Malignancies
February 14th 2025, 9:57pm
Transplantation and Cellular Therapy Meetings
Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.
Enfortumab Vedotin/Pembrolizumab Elicits Radiographic Responses in Primary UTUC Lesions
February 14th 2025, 9:35pm
Genitourinary Cancers Symposium (ASCO GU)
Enfortumab vedotin, both as monotherapy and in combination with pembrolizumab, demonstrated clinical activity in patients with UTUC lesions.
Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis
February 14th 2025, 9:30pm
Transplantation and Cellular Therapy Meetings
Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.
Updated CheckMate-274 Data Further Support Adjuvant Nivolumab as SOC for High-Risk MIUC
February 14th 2025, 8:44pm
Genitourinary Cancers Symposium (ASCO GU)
Consistent DFS benefit was observed with adjuvant nivolumab vs placebo in all patients with muscle-invasive bladder cancer enrolled in CheckMate-274.
Real-World Data Show Enfortumab Vedotin Significantly Improves OS in Urothelial Carcinoma
February 14th 2025, 8:27pm
Genitourinary Cancers Symposium (ASCO GU)
Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.
Axatilimab, Ruxolitinib, and Belumosudil Combo Elicits Responses in Chronic GVHD
February 14th 2025, 7:47pm
Transplantation and Cellular Therapy Meetings
Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.
Transdermal Estradiol Plus ARPIs Demonstrate Comparable PSA Response to LHRHa in Metastatic Prostate Cancer
February 14th 2025, 6:15pm
Genitourinary Cancers Symposium (ASCO GU)
Responses were similar among patients with estrogen patches and ARPIs compared to aLHRH and ARPIs in metastatic prostate cancer.
Dr Shah on Efficacy Data for Zamto-Cel in R/R DLBCL
February 14th 2025, 6:01pm
Transplantation and Cellular Therapy Meetings
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma
Dr Dholaria on the Safety and Efficacy of P-BCMA-ALLO1 in R/R Myeloma
February 14th 2025, 5:58pm
Transplantation and Cellular Therapy Meetings
Dr Dholaria discusses the phase 1 trial of P-BCMA-ALLO1, highlighting high response rates, rapid CAR T-cell expansion, and a favorable safety profile in RRMM.
Dr Ahmed on NKTR-255 With CD19-Directed CAR T-Cell Therapy in R/R LBCL
February 14th 2025, 5:24pm
Transplantation and Cellular Therapy Meetings
Sairah Ahmed, MD, discusses evaluating NKTR-255 in combination with CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.
P-BCMA-ALLO1 Is Safe and Efficacious in R/R Multiple Myeloma
February 14th 2025, 5:22pm
Transplantation and Cellular Therapy Meetings
P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.
Zamto-Cel Delivers Responses in R/R Diffuse Large B-Cell Lymphoma
February 14th 2025, 4:22pm
Transplantation and Cellular Therapy Meetings
Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.